Logo image of BCRX

BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis

NASDAQ:BCRX - US09058V1035 - Common Stock

8.56 USD
+0.18 (+2.15%)
Last: 8/22/2025, 8:00:02 PM
8.56 USD
0 (0%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

4

Overall BCRX gets a fundamental rating of 4 out of 10. We evaluated BCRX against 547 industry peers in the Biotechnology industry. Both the profitability and the financial health of BCRX get a neutral evaluation. Nothing too spectacular is happening here. BCRX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BCRX has reported negative net income.
In the past year BCRX had a positive cash flow from operations.
BCRX had negative earnings in each of the past 5 years.
BCRX had a negative operating cash flow in each of the past 5 years.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

BCRX's Return On Assets of -7.81% is amongst the best of the industry. BCRX outperforms 85.06% of its industry peers.
The Return On Invested Capital of BCRX (15.29%) is better than 96.36% of its industry peers.
Industry RankSector Rank
ROA -7.81%
ROE N/A
ROIC 15.29%
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

BCRX has a Operating Margin of 9.72%. This is amongst the best in the industry. BCRX outperforms 92.71% of its industry peers.
Looking at the Gross Margin, with a value of 97.00%, BCRX belongs to the top of the industry, outperforming 96.17% of the companies in the same industry.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
Industry RankSector Rank
OM 9.72%
PM (TTM) N/A
GM 97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BCRX is creating some value.
The number of shares outstanding for BCRX has been increased compared to 1 year ago.
Compared to 5 years ago, BCRX has more shares outstanding
BCRX has a worse debt/assets ratio than last year.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.99, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.99, BCRX perfoms like the industry average, outperforming 53.01% of the companies in the same industry.
The Debt to FCF ratio of BCRX is 1038.46, which is on the high side as it means it would take BCRX, 1038.46 years of fcf income to pay off all of its debts.
BCRX's Debt to FCF ratio of 1038.46 is amongst the best of the industry. BCRX outperforms 91.07% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1038.46
Altman-Z -1.99
ROIC/WACC1.71
WACC8.92%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

BCRX has a Current Ratio of 2.25. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BCRX (2.25) is worse than 71.95% of its industry peers.
BCRX has a Quick Ratio of 2.21. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
BCRX has a worse Quick ratio (2.21) than 70.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.21
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.14% over the past year.
BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 45.85%.
The Revenue has been growing by 55.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)45.85%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%49.41%

3.2 Future

BCRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.12% yearly.
The Revenue is expected to grow by 14.39% on average over the next years. This is quite good.
EPS Next Y120.37%
EPS Next 2Y83.17%
EPS Next 3Y53.92%
EPS Next 5Y37.12%
Revenue Next Year38.88%
Revenue Next 2Y22.22%
Revenue Next 3Y18.48%
Revenue Next 5Y14.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 14.69 indicates a correct valuation of BCRX.
Based on the Price/Forward Earnings ratio, BCRX is valued cheaper than 95.08% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.81. BCRX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 14.69
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

BCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BCRX is cheaper than 91.80% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BCRX is valued cheaply inside the industry as 91.07% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2556.07
EV/EBITDA 37.76
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

BCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 53.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83.17%
EPS Next 3Y53.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (8/22/2025, 8:00:02 PM)

After market: 8.56 0 (0%)

8.56

+0.18 (+2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners85.83%
Inst Owner Change16.15%
Ins Owners1.12%
Ins Owner Change5.27%
Market Cap1.80B
Analysts83.33
Price Target17.99 (110.16%)
Short Float %12.76%
Short Ratio7.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)140.06%
Min EPS beat(2)100%
Max EPS beat(2)180.11%
EPS beat(4)2
Avg EPS beat(4)37.5%
Min EPS beat(4)-123.6%
Max EPS beat(4)180.11%
EPS beat(8)5
Avg EPS beat(8)30.61%
EPS beat(12)7
Avg EPS beat(12)12.7%
EPS beat(16)9
Avg EPS beat(16)13.24%
Revenue beat(2)2
Avg Revenue beat(2)9.71%
Min Revenue beat(2)6.96%
Max Revenue beat(2)12.47%
Revenue beat(4)3
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-0.92%
Max Revenue beat(4)12.47%
Revenue beat(8)6
Avg Revenue beat(8)4.56%
Revenue beat(12)7
Avg Revenue beat(12)2.76%
Revenue beat(16)8
Avg Revenue beat(16)1.37%
PT rev (1m)0.52%
PT rev (3m)2.74%
EPS NQ rev (1m)-24.99%
EPS NQ rev (3m)336.1%
EPS NY rev (1m)-22.4%
EPS NY rev (3m)183.09%
Revenue NQ rev (1m)3.4%
Revenue NQ rev (3m)12.57%
Revenue NY rev (1m)2.07%
Revenue NY rev (3m)3.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.69
P/S 3.22
P/FCF 2556.07
P/OCF 1021.56
P/B N/A
P/tB N/A
EV/EBITDA 37.76
EPS(TTM)-0.16
EYN/A
EPS(NY)0.58
Fwd EY6.81%
FCF(TTM)0
FCFY0.04%
OCF(TTM)0.01
OCFY0.1%
SpS2.66
BVpS-2.01
TBVpS-2.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.81%
ROE N/A
ROCE 19.35%
ROIC 15.29%
ROICexc 214.19%
ROICexgc 214.19%
OM 9.72%
PM (TTM) N/A
GM 97%
FCFM 0.13%
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score5
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1038.46
Debt/EBITDA 12.49
Cap/Depr 82.5%
Cap/Sales 0.19%
Interest Coverage 1.46
Cash Conversion 3.17%
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 2.21
Altman-Z -1.99
F-Score5
WACC8.92%
ROIC/WACC1.71
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next Y120.37%
EPS Next 2Y83.17%
EPS Next 3Y53.92%
EPS Next 5Y37.12%
Revenue 1Y (TTM)45.85%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%49.41%
Revenue Next Year38.88%
Revenue Next 2Y22.22%
Revenue Next 3Y18.48%
Revenue Next 5Y14.39%
EBIT growth 1Y189.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year598.43%
EBIT Next 3Y129.66%
EBIT Next 5YN/A
FCF growth 1Y100.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.44%
OCF growth 3YN/A
OCF growth 5YN/A